Overview

A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Status:
Recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

It's a double-blind , randomized ,multi-center study. The purpose of this study is to explore the efficacy and safety of flumatinib 400mg once daily (QD) versus 600mg QD as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).

Phase:

Phase 4

Details

Lead Sponsor:

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Treatments:

HH-GV-678